TORONTO, April 29 /CNW/ - 3i Investments plc of London, England announces that 3i Group plc (hereinafter referred to as "3i") and 3i Bioscience Investment Trust plc ("3i Bioscience") have purchased 6,772,469 common shares of Inflazyme Pharmaceuticals Ltd. As a result of the purchase, 3i holds 5,079,315 common shares (or 5.431%) of Inflazyme's common stock and 3i Bioscience holds 4,683,154 common shares (or 5.007%) of Inflazyme's common stock. 3i and 3i Bioscience received the shares of Inflazyme as consideration for the sale of shares in Adprotech Ltd. The purchases have been made for investment purposes only, and not with the purpose of influencing the control or direction of Inflazyme. 3i and 3i Bioscience may, subject to market conditions, make additional investments in or dispositions of securities of Inflazyme, including additional purchases or sales of shares of common stock. 3i and 3i Bioscience do not, however, intend to acquire 20% of any class of the outstanding voting or equity securities of Inflazyme. -0- 04/29/2004 /For further information: please contact Andy Smith, 3i Investments plc, 91 Waterloo Road, London, SE1 8XP, England, Tel: +44 (0) 20 7975 3144, Fax: +44 (0) 20 7975 3014/ CO: 3i Investments plc ST: Ontario IN: SU: TNM -30- -0- Apr/29/2004 20:14 GMT
Patrick Pouyanne Said to Be Named New Total CEO
3i Investments plc
Press spacebar to pause and continue. Press esc to stop.